TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

por Mohanan, Anookh, Gupta, Ram, Dubey, Amita, Jagtap, Vikrant, Mandhare, Appaji, Gupta, Ramesh C., Chauthaiwale, Vijay, Dutt, Chaitanya
Publicado 2011

Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial

por Joshi, Deepa, Jamadarkhana, Prashant, Kumbhare, Suchit, Singh, Amarinder, Kotecha, Jignesh, Bunger, Deepak, Shiwalkar, Ajay, Mohanan, Anookh, Dutt, Chaitanya
Publicado 2021

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

por Joshi, Deepa, GJ, Prashant, Ghosh, Shohini, Mohanan, Anookh, Joshi, Shashank, Mohan, Viswanathan, Chowdhury, Subhankar, Dutt, Chaitanya, Tandon, Nikhil
Publicado 2022

The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial

por van der Valk, Fleur, Hassing, Carlijne, Visser, Maartje, Thakkar, Purav, Mohanan, Anookh, Pathak, Kaushal, Dutt, Chaitanya, Chauthaiwale, Vijay, Ackermans, Mariette, Nederveen, Aart, Serlie, Mireille, Nieuwdorp, Max, Stroes, Erik
Publicado 2014